Free press releases distribution network?

Agency / Source: Alto Marketing Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biocompatibles Launch CelLuminate™ Intracellular Delivery System - Prize draw open to EMBO delegates and online registrants
Biocompatibles Launch CelLuminate™ Intracellular Delivery System


PRZOOM - /newswire/ - Farnham, Surrey, United Kingdom, 2009/08/25 - Prize draw open to EMBO delegates and online registrants.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


UK company Biocompatibles is launching a new product in its CelLuminate™ range of intracellular delivery systems, at EMBO 2009 in Amsterdam on the 29th August – 1st September. The new CelLuminate™ VPS (Vesicle-forming Polymer System) improves the efficiency of intracellular delivery of bioactive molecules compared to conventional liposomal systems. It can deliver anything from fluorophores to RNA, DNA and proteins – efficiently and with minimal cytotoxic effects. To celebrate the launch, Biocompatibles ( is giving away 10 samples of CelLuminate VPS (worth £200 each) in a prize draw. To enter the draw, researchers will need to visit Biocompatibles on Stand 29 at EMBO. Those not attending the conference can enter the draw by clicking the online link below. The draw closes at 4pm on Monday 14th September 2009.

CelLuminate is made from proprietary biomimetic copolymer and exploits the natural cellular endocytotic pathways. As the surface chemistry of the vesicles mimics that of cell membranes, the rate and amount of vesicles endocytosed is orders of magnitude higher than conventional liposomal systems. Being pH-sensitive, the CelLuminate vesicles utilise the pH drop in the endosome to deliver the desired payload into the cell cytosol. CelLuminate VPS is designed so that researchers can prepare their own vesicles to encapsulate any bioactive agent, easily and without experience.

CelLuminate VPS (, has been developed following requests from researchers using the CelLuminate Red rhodamine-loaded cell staining system, which was launched earlier this year. CelLuminate Red has enabled improved cell fluorescence studies, as cells can live for up to two weeks and fluorescence lasts longer. “We know that researchers find that CelLuminate is easy to use and practical” said Tim Maloney, Biocompatibles’ Marketing Director. “Speaking with researchers who were using CelLuminate Red, it was clear that many also wanted to use the CelLuminate vesicle delivery system to deliver their own fluorescent probes, and other bioactive molecules – which led to the development of CelLuminate VPS. As we are still exploring the potential of the system, we wanted to offer researchers the opportunity to trial CelLuminate VPS at no cost, and the ideal way to do this was in a prize draw.

For more information and to enter the prize draw please visit our site or see Biocompatibles on Stand A29 at EMBO 2009.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Alto Marketing Ltd


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Biocompatibles Launch CelLuminate™ Intracellular Delivery System

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Contact: Leigh Dilley 
+44 1489 557672 clarer[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Alto Marketing Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From Alto Marketing Ltd / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...


Visit  Intrinsic Executive Search Ltd

Visit  MagLar, Inc.


  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today